The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I trial: Pretransplant targeting of multiple myeloma stem cell (MMSC) with armed activated T cells (aATC).
Z. S. Al-Kadhimi
No relevant relationships to disclose
A. Thakur
No relevant relationships to disclose
E. Tomaszewski
No relevant relationships to disclose
M. H. Abidi
No relevant relationships to disclose
J. A. Zonder
No relevant relationships to disclose
V. Ratanatharathorn
No relevant relationships to disclose
L. J. Ayash
No relevant relationships to disclose
A. Deol
No relevant relationships to disclose
P. Steele
No relevant relationships to disclose
K. Myers
No relevant relationships to disclose
J. P. Uberti
No relevant relationships to disclose
L. G. Lum
Stock Ownership - TransTarget